Osprey Private Wealth LLC Boosts Stock Holdings in Danaher Corporation $DHR

Osprey Private Wealth LLC raised its holdings in Danaher Corporation (NYSE:DHR) by 40.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,375 shares of the conglomerate’s stock after purchasing an additional 4,425 shares during the quarter. Osprey Private Wealth LLC’s holdings in Danaher were worth $3,048,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the business. Norges Bank acquired a new stake in shares of Danaher in the 2nd quarter valued at approximately $1,979,503,000. Viking Global Investors LP lifted its holdings in Danaher by 543.9% in the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after acquiring an additional 2,455,994 shares during the period. Generation Investment Management LLP lifted its holdings in Danaher by 56.2% in the second quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after acquiring an additional 1,787,522 shares during the period. Primecap Management Co. CA boosted its position in shares of Danaher by 924.2% during the 2nd quarter. Primecap Management Co. CA now owns 1,239,320 shares of the conglomerate’s stock worth $244,815,000 after purchasing an additional 1,118,318 shares in the last quarter. Finally, Baird Financial Group Inc. grew its stake in shares of Danaher by 290.6% during the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock worth $295,550,000 after purchasing an additional 1,072,617 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Danaher

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Teri List sold 3,298 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director owned 20,762 shares of the company’s stock, valued at $4,702,593. This trade represents a 13.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,248 shares of company stock worth $6,609,663 over the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

Danaher Price Performance

DHR stock opened at $222.91 on Thursday. The stock’s 50 day moving average price is $219.53 and its 200 day moving average price is $206.53. The firm has a market cap of $157.45 billion, a P/E ratio of 45.96, a PEG ratio of 4.36 and a beta of 0.89. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.71 earnings per share. On average, sell-side analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of research analyst reports. Cowen reissued a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. Redburn Partners set a $220.00 price target on shares of Danaher in a research report on Wednesday, October 8th. The Goldman Sachs Group started coverage on Danaher in a report on Tuesday, December 9th. They issued a “buy” rating and a $265.00 price target on the stock. Rothschild Redb downgraded Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Twenty research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $248.25.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.